Tivozanib, a cancer drug developed by AVEO Pharmaceuticals (AVEO +0.00%) and Astellas Pharma, is currently under FDA review. Shares of AVEO fell by 5% today after reporting its Q4 results and offering additional details from tivozanib's phase 3 clinical trial. This news has largely been expected by investors since last summer, and health care analyst Max Macaluso breaks down what happened today in this video.
Why Shares of AVEO Hit the Brakes Today
By Max Macaluso – Feb 13, 2013 at 6:00PM
NASDAQ: AVEO
Aveo Pharmaceuticals
AVEO releases information regarding overall survival.
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo